Aspire Biopharma Holdings (ASBP) Research & Development (2024 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Research & Development of $334739.0 for Q1 2026, up 27.23% year-over-year from $263093.0 in Q1 2025, and up 259.2% quarter-over-quarter from $93190.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Research & Development (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Research & Development for 3 consecutive years, with $334739.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 27.23% year-over-year to $334739.0; the TTM figure through Mar 2026 stood at $687139.0 (up 81.45% YoY), while the FY2025 annual figure was $789829.0, up 526.38% from the prior year.
- Research & Development grew to $334739.0 in Q1 2026 per ASBP's latest filing, from $93190.0 in the prior quarter.
- Across five years, Research & Development topped out at $334739.0 in Q1 2026 and bottomed at $7000.0 in Q3 2024.
- Historically, Research & Development has averaged $128165.8 across 3 years, with a median of $93190.0 in 2025.
- On a YoY basis, Research & Development climbed as much as 2869.99% in 2025 and fell as far as 5.0% in 2025.
- Aspire Biopharma Holdings' Research & Development stood at $98094.0 in 2024, then dropped by 5.0% to $93190.0 in 2025, then jumped by 259.2% to $334739.0 in 2026.
- Business Quant data shows ASBP's Research & Development at $334739.0 in Q1 2026, $93190.0 in Q4 2025, and $207899.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 97.90 Mn |
| 10 | Aspire Biopharma Holdings | 8.39 Mn | -3.78 Mn | -30,086.00 | 1.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.22 Mn |
| Mar 31, 2026 | 334,739.00 |
| Dec 31, 2025 | 93,190.00 |
| Sep 30, 2025 | 207,899.00 |
| Jun 30, 2025 | 51,311.00 |
| Mar 31, 2025 | 263,093.00 |
| Dec 31, 2024 | 98,094.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 10,500.00 |
| Mar 31, 2024 | 87,666.00 |